Medexus Pharmaceuticals (TSX:MDP) Change In Payables And Accrued Expense : C$-4.8 Mil (TTM As of Dec. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Change In Payables And Accrued Expense?

Medexus Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Dec. 2024 was C$3.8 Mil. It means Medexus Pharmaceuticals's Accounts Payable & Accrued Expense increased by C$3.8 Mil from Sep. 2024 to Dec. 2024 .

Medexus Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Mar. 2024 was C$11.6 Mil. It means Medexus Pharmaceuticals's Accounts Payable & Accrued Expense increased by C$11.6 Mil from Mar. 2023 to Mar. 2024 .

Medexus Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Medexus Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Change In Payables And Accrued Expense Chart

Medexus Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

6.92

5.81

4.56

6.50

11.62

Medexus Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															12.11	-1.48	-10.21	3.05	3.81

Medexus Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.8 Mil.

Medexus Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Medexus Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Medexus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

MEDXF:USA P731:Germany

Address

10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3

Website

https://www.medexus.com

Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.

Executives

Brendon Buschman	Senior Officer
Mike Mueller	Director
Benoit Gravel	Director
Stephen William Nelson	Director
Kenneth D'entremont	Director, Senior Officer
Marcel Pascal Konrad	Senior Officer
Michael David Adelman	Senior Officer
Glenn Tate	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Brian Peters	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin	Senior Officer
Michael Pine	Senior Officer
Richard Labelle	Senior Officer
Benoît Hébert	Senior Officer